Integral Health Asset Management’s Erasca ERAS Stock Holding History

Integral Health Asset Management’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3M	Buy	+700,000	New	+$8.27M	0.54%	48

Other funds holding ERAS

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

T. Rowe Price Investment Management

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Integral Health Asset Management's ERAS Position: Q1 2026 in Review

Integral Health Asset Management opened a new position in Erasca (ERAS) in Q1 2026: 700,000 shares worth $11.3M. The stake represents 0.54% of the portfolio and ranks #48 among its holdings.

225 funds tracked by Wall St. Rank hold ERAS as of Q1 2026.

Integral Health Asset Management held 700,000 shares of Erasca worth $11.3M as of Q1 2026.
Erasca was a new Integral Health Asset Management position in Q1 2026.
Erasca made up 0.54% of Integral Health Asset Management's portfolio in Q1 2026, its #48 holding.
225 funds tracked by Wall St. Rank held Erasca as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.